Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells $438,898.44 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 9,102 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the sale, the chief executive officer now directly owns 115,920 shares of the company’s stock, valued at approximately $5,589,662.40. This represents a 7.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $50.21 on Wednesday. The company has a market capitalization of $2.41 billion, a PE ratio of -24.86 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The company’s 50 day moving average price is $44.39 and its 200 day moving average price is $42.02. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $50.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.57) earnings per share. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares during the last quarter. Legato Capital Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 7.9% during the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after purchasing an additional 977 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after purchasing an additional 1,003 shares during the last quarter. Rhumbline Advisers boosted its holdings in Mirum Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock worth $2,196,000 after purchasing an additional 1,236 shares in the last quarter. Finally, R Squared Ltd acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $69,000.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Citigroup increased their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Leerink Partners upped their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.